BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J Gastroenterol Hepatol 2015;30:155-62. [PMID: 25041076 DOI: 10.1111/jgh.12657] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Rossini E, Biscetti F, Rando MM, Nardella E, Cecchini AL, Nicolazzi MA, Covino M, Gasbarrini A, Massetti M, Flex A. Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? IJMS 2022;23:9326. [DOI: 10.3390/ijms23169326] [Reference Citation Analysis]
2 Prasomthong J, Limpeanchob N, Daodee S, Chonpathompikunlert P, Tunsophon S. Hibiscus sabdariffa extract improves hepatic steatosis, partially through IRS-1/Akt and Nrf2 signaling pathways in rats fed a high fat diet. Sci Rep 2022;12:7022. [PMID: 35487948 DOI: 10.1038/s41598-022-11027-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Shen M, Yao S, Li S, Wu X, Liu S, Yang Q, Du J, Wang J, Zheng X, Li Y. A ROS and shear stress dual-sensitive bionic system with cross-linked dendrimers for atherosclerosis therapy. Nanoscale 2021;13:20013-27. [PMID: 34842887 DOI: 10.1039/d1nr05355h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hu N, Chen C, Wang J, Huang J, Yao D, Li C. Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. Int J Mol Sci 2021;22:11107. [PMID: 34681767 DOI: 10.3390/ijms222011107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Komamine M, Fujimura Y, Nitta Y, Omiya M, Doi M, Sato T. Characteristics of hospital differences in missing of clinical laboratory test results in a multi-hospital observational database contributing to MID-NET® in Japan. BMC Med Inform Decis Mak 2021;21:181. [PMID: 34090442 DOI: 10.1186/s12911-021-01543-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
7 Bastani M, Khosravi MB, Shafa M, Azemati S, Maghsoodi B, Asadpour E. Evaluation of high-dose atorvastatin pretreatment influence in patients preconditioning of post coronary artery bypass graft surgery: A prospective triple blind randomized clinical trial. Ann Card Anaesth 2021;24:209-16. [PMID: 33884978 DOI: 10.4103/aca.ACA_34_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Alfarisi HAH, Ibrahim MB, Mohamed ZBH, Azahari N, Hamdan AHB, Che Mohamad CA. Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. ScientificWorldJournal 2020;2020:4503253. [PMID: 33132768 DOI: 10.1155/2020/4503253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Arenz K, Dhillon R, Enright N, Gupta A, Varghese M. Are statins indicated for use in patients with chronic liver injury? EBPR 2021;24:23-24. [DOI: 10.1097/ebp.0000000000000984] [Reference Citation Analysis]
10 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020;69:953-62. [PMID: 32139553 DOI: 10.1136/gutjnl-2019-318237] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
11 Sharkawi SMZ, El-Shoura EAM, Abo-Youssef AM, Hemeida RAM. The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats. Immunopharmacol Immunotoxicol 2020;42:165-73. [PMID: 32114843 DOI: 10.1080/08923973.2020.1733013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Meurer L, Cohen SM. Drug-Induced Liver Injury from Statins. Clin Liver Dis 2020;24:107-19. [PMID: 31753243 DOI: 10.1016/j.cld.2019.09.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
13 Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
14 Chao CT, Wang J, Huang JW, Chien KL. Acarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort Study. Front Pharmacol. 2018;9:860. [PMID: 30131698 DOI: 10.3389/fphar.2018.00860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
15 Karahalil B, Hare E, Koç G, Uslu İ, Şentürk K, Özkan Y. Hepatotoxicity associated with statins. Archives of Industrial Hygiene and Toxicology 2017;68:254-60. [DOI: 10.1515/aiht-2017-68-2994] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
16 Ma X, Sun D, Li C, Ying J, Yan Y. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:533-42. [PMID: 28866088 DOI: 10.1016/j.clinre.2017.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral arterial disease. Journal of Vascular Surgery 2016;64:1881-8. [DOI: 10.1016/j.jvs.2016.08.094] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
18 Benes LB, Bassi NS, Davidson MH. The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Progress in Cardiovascular Diseases 2016;59:145-52. [DOI: 10.1016/j.pcad.2016.08.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
19 Wang LY, Huang YS, Perng CL, Huang B, Lin HC. Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. Br J Clin Pharmacol 2016;82:823-30. [PMID: 27197051 DOI: 10.1111/bcp.13009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
20 Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". J Am Heart Assoc 2016;5:e002683. [PMID: 27130349 DOI: 10.1161/JAHA.115.002683] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
21 Kao CC, Wu PC, Wu CH, Chen LK, Chen HH, Wu MS, Wu VC. Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients. Sci Rep 2016;6:18996. [PMID: 26751038 DOI: 10.1038/srep18996] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke. 2016;47:441-449. [PMID: 26732563 DOI: 10.1161/strokeaha.115.011476] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
23 Rengo JL, Callahan DM, Savage PD, Ades PA, Toth MJ. Skeletal muscle ultrastructure and function in statin-tolerant individuals. Muscle Nerve 2016;53:242-51. [PMID: 26059690 DOI: 10.1002/mus.24722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
24 Björkhem-Bergman L. Is There a Role for Statins in Palliative Care for Patients Suffering from Hepatocellular Carcinoma? J Palliat Care 2015;31:172-6. [PMID: 26514023 DOI: 10.1177/082585971503100307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung RT, Rogal SS; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology 2015;62:365-74. [PMID: 25847403 DOI: 10.1002/hep.27835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
26 Bosch J, Forns X. Therapy. Statins and liver disease: from concern to 'wonder' drugs? Nat Rev Gastroenterol Hepatol 2015;12:320-1. [PMID: 25963509 DOI: 10.1038/nrgastro.2015.78] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
27 Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol. 2015;89:1175-1191. [PMID: 25975988 DOI: 10.1007/s00204-015-1521-x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 13.9] [Reference Citation Analysis]